Warner Chilcott Considers Repricing Counter
Warner Chilcott wasn’t able to secure approval for the proposed repricing on its $2.1 billion term loan to finance its acquisition of Procter & Gamble’s prescription drug unit.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast